Drug intelligence / Profile preview

abituzumab

Development stage: Phase 2
Lead developer: Merck KGaA
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Abituzumab is a humanized IgG2 monoclonal antibody that targets CD51 (integrin alphaV), also known as the vitronectin receptor. By binding to and inhibiting the activity of integrin alphaVbeta3, abituzumab disrupts endothelial cell-cell and cell-matrix interactions, which may inhibit tumor angiogenesis and metastasis. It has been investigated primarily for its potential to prevent bone lesion metastases in castration-resistant prostate cancer and for use in solid tumors such as colorectal cancer. The drug was developed by Merck Serono (a division of Merck KGaA) and SFJ Pharmaceuticals[1][3][5].

Other names: anti-CD51 antigen mAbanti-CD-51 antigen mAbanti-CD 51 antigen mAbanti-integrin alphaV mAb

Targets

ITGAV (Integrin αV)

Beyond the preview

Go deeper on abituzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abituzumab.

Explore the full profile